Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(45.5%)

Phase 3

4(36.4%)

Phase 1

2(18.2%)

11Total

Phase 2(5)

Phase 3(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT00841594Phase 1Completed

MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison

Role: lead

NCT00934427Phase 3Unknown

Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms

Role: lead

NCT00577304Phase 3Unknown

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

Role: lead

NCT00666354Phase 2Unknown

Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis

Role: lead

NCT00513994Phase 1Completed

MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects

Role: lead

NCT00480753Phase 2Completed

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

Role: lead

NCT00266669Phase 3Completed

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

Role: lead

NCT00253305Phase 2Completed

Topical Gel Anti-Fungal Agent for Tinea Unguium

Role: lead

NCT00253331Phase 2Completed

Lab Study of MQX-503 in Treatment of Raynaud's

Role: lead

NCT00378521Phase 2Completed

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

Role: lead

NCT00419419Phase 3Completed

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

Role: lead

All 11 trials loaded